However, the overexpression of either SP1 or LOXL2 did not significantly correlate with poor clinical outcomes including lymph node metastasis, depth of invasion, or lymphovascular invasion. Here, LOXL2 is linked to metastatic malignant neoplasm in the lymph nodes.